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ABSTRACT
Multiple myeloma (MM) is the second most common hematologic malignancy. 
While major advances have been made in the disease, it is still incurable. Although 
antifolate-based drugs are not commonly used to treat myeloma, new generation 
analogs with distinct patterns of preclinical and clinical activity may offer an 
opportunity to identify new classes of potentially active drugs. Pralatrexate (PDX), 
which was approved for the treatment of relapsed or refractory peripheral T-cell 
lymphoma in 2009, may be one such drug. Pralatrexate exhibits a potency and pattern 
of activity distinct from its predecessors like methotrexate (MTX). We sought to 
understand the activity and mechanisms of resistance of multiple myeloma to these 
drugs, which could also offer potential strategies for selective use of the drug. We 
demonstrate that PDX and MTX both induce a significant decrease in cell viability in 
the low nanomolar range, with PDX exhibiting a more potent effect. We identified a 
series of myeloma cell lines exhibiting markedly different patterns of sensitivity to 
the drugs, with some lines frankly resistant, and others exquisitely sensitive. These 
differences were largely attributed to the basal RFC (Reduced Folate Carrier) mRNA 
expression levels. RFC mRNA expression correlated directly with rates of drug uptake, 
with the most sensitive lines exhibiting the most significant intracellular accumulation 
of pralatrexate. This mechanism explains the widely varying patterns of sensitivity and 
resistance to pralatrexate in multiple myeloma cell lines. These findings could have 
implications for this class of drugs and their role in the treatment of multiple myeloma.
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INTRODUCTION
Multiple myeloma (MM) is a malignancy of 
immunoglobulin-secreting plasma cells, and is considered 
the second most common hematologic malignancy. Despite 
the introduction of many effective drugs over the past 
decades, the disease is widely considered incurable [1]. 
Incomplete eradication of the disease has been attributed, 
at least in part, to heterogeneity and clonal evolution of 
the malignant plasma cell population [2, 3]. Recent studies 
utilizing advances in single-cell sequencing and whole 
exome profiling have identified subclonal tumor cell 
populations present at initial treatment which expand over 
time, producing increasingly drug resistant phenotypes [4]. 
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Identification of functional biomarkers which correlate 
with sensitivity or resistance to a particular drug or class of 
drugs is a principle component of the “precision medicine” 
approach to treat many malignant diseases, including 
relapsed multiple myeloma [5]. In theory, the integration 
of novel agents into a tailored treatment strategy based on 
the patients’ disease biology could increase the probability 
of favorable outcome.
Pralatrexate (PDX, 10-propargyl 10-deazaaminopterin) 
is a folate analogue rationally designed to have greater 
affinity (more than 10-fold greater affinity compared to 
methotrexate) for RFC, and has proven more potent than 
methotrexate (MTX) [6, 7]. The RFC transporter is an 
oncofetal protein shown to be more highly expressed on 
fetal and malignant tissue, and is the primary mechanism for 
internalization of the drug into the tumor cell. The activity 
of PDX in peripheral T-cell lymphoma (PTCL) likely goes 
beyond its effects as an inhibitor of dihydrofolate reductase 
(DHFR), a hypothesis supported by the observation that 
leucovorin can be given concomitantly with pralatrexate 
without compromise of its activity in both preclinical and 
clinical settings [8, 9]. Additionally, pralatrexate has greater 
affinity for folylpolyglutamate synthase (FPGS), which 
mediates polyglutamylation of the drug, leading to prolonged 
intracellular retention [10–13]. Pralatrexate inhibits tumor 
growth with more potency than other antifolates across a host 
of cancer cell models [14, 15]. In particular, pralatrexate has 
exhibited marked activity in T-cell malignancies in both the 
preclinical and clinical setting, which led to it becoming the 
first drug approved for patients with relapsed or refractory 
PTCL. The activity in PTCL appears out of proportion to what 
has been described in B-cell malignancies and solid tumors 
studied to date [16–24]. While the basis for this activity in 
PTCL is a matter of continued research, it raises the question 
as to why some malignant diseases exhibit such intrinsic 
resistance, while others an intrinsic vulnerability to the drug.
A number of pharmacologic determinants 
that correlate with methotrexate resistance have 
been established, including DHFR, FPGS, gamma-
glutamyl hydrolase (GGH) and RFC [25–30]. The first 
demonstration of a relationship between one of these 
determinants and methotrexate resistance was established 
by Bertino and Shimke, who described gene amplification 
of DHFR as a mechanism of resistance to MTX in a colon 
carcinoma and acute leukemia cell lines [31–33]. Several 
papers have established a correlation between functional 
RFC protein expression and MTX sensitivity, including 
studies in human T-cell acute lymphoblastic leukemia cells, 
and solid tumor cell lines [34]. In one study, treatment 
with methotrexate reduced DHFR gene expression while 
increasing RFC mRNA in sensitive cell lines, which did 
not occur in MTX resistant cells [35]. While correlations 
with these pharmacologic determinants and drug sensitivity 
have been demonstrated in select disease settings for 
MTX, little to no data have established these determinants 
for pralatrexate in any biological setting.
Drug screens in our laboratory indicate that some 
myeloma cell lines exhibit marked sensitivity to PDX and 
MTX, while others maintain a more resistant phenotype. 
Based on these findings, we sought to better understand 
the mechanisms of intrinsic resistance and sensitivity, in 
anticipation of identifying strategies to optimize the drug 
in myeloma and other malignant diseases.
RESULTS
Comparison of MTX and pralatrexate 
cytotoxicity
Figure 1 presents the concentration effect 
relationships for MTX and pralatrexate in the panel of 
myeloma lines. Both MTX and PDX caused significant 
reduction in cellular ATP levels in a subset of myeloma 
cell lines, with pralatrexate appearing about a log more 
potent in sensitive lines compared to MTX. No cell 
line exhibited sensitivity to only one antifolate, with 
all lines either sensitive to MTX and pralatrexate, or 
resistant to both agents The myeloma cell lines appeared 
to segregate into two distinct groups based on their 
patterns of sensitivity. The myeloma cells lines MM.1s, 
ARH-77, KMS-11 and PCNY-1B exhibited marked 
sensitivity to both drugs, with pralatrexate exhibiting 
higher potency compared to MTX for all lines (PDX IC
50
: 
1.7–9.7 nM vs MTX IC
50
: 22.7–40.9 nM; Figure 1A, 1B). 
Conversely, SK-MM2, U266, RPMI, ARP-1 and CAG 
cell lines exhibited marked resistance with very high 
IC
50
 concentrations or no sensitivity at all at the highest 
concentrations (Figure 1C). All responses in the sensitive 
myeloma cell lines were both time and concentration 
dependent (Supplementary Figure 1). While select lines 
exhibited cytotoxicity at 24 hours, the maximum effect 
was achieved at 48 hours, with no increase in cell death 
observed at 72 hours of incubation.
Induction of apoptosis
Loss of cell viability was corroborated by examining 
induction of apoptosis in drug-treated cells through 
Annexin V and caspase staining. In general, the same 
patterns of sensitivity and resistance noted in the cell 
viability experiments were observed in the apoptosis 
assays. Across all cell lines studied, pralatrexate was 
more potent than MTX, and no cell line exhibited 
sensitivity to only one of the two drugs studied. For 
example, as shown in Figure 2A, MM.1s cells exhibited 
a concentration dependent induction of apoptosis to 
both MTX and pralatrexate, with the latter occurring 
at about a log lower than what was observed for MTX. 
Treatment of MM.1s, KMS-11 and PCNY-1B cells with 
increasing concentrations of pralatrexate or MTX for 
48 hours resulted in a concentration dependent increase 
in apoptosis, quantified as the AnnexinV+ cell population 
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Figure 1: Dose-response curves for antifolates in a panel of HMCLs. Human multiple myeloma cell lines (HMCLs) were 
incubated with increasing concentrations of (A) pralatrexate (PDX) or (B) methotrexate (MTX) for 48 hrs. The HMCLs segregated into 
sensitive (open icons: ARH-77, MM.1s, KMS-11, PCNY-1B) or resistant (filled icons: U266, CAG, RPMI 8226) groupings. (C) An ordered 
list of half maximal inhibitory concentration (IC
50
) values for PDX and MTX in HMCLs. The values were determined using an ordinary 
least squares nonlinear curve fitting method and the goodness of fit was determined valid with an R2 > 0. The curves were normalized to 
untreated cells (100%) and bortezomib (10–50 nM) treated cells (0%). Data represent the mean ± SD of at least three experiments. Cell 
viability was determined by an ATP-dependent luciferase-based reporter assay.
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(Supplementary Figure 2A, 2B). Again, the same cell lines 
classified as sensitive in the Cell Titer Glo Assay were 
sensitive in the apoptosis assays. The resistant myeloma 
cell lines, including U266, CAG and ARP-1 exhibited 
no significant increases in apoptosis compared to vehicle 
treated controls across a broad concentration range of 
either MTX or pralatrexate. The differences observed 
in apoptotic cell numbers between sensitive cell lines 
(MM.1s and KMS-11) and resistant cell lines (U266, ARP-
1) were significant at 48 hours after exposure to 10 nM 
PDX (Figure 2B). These data corroborate the cytotoxicity 
results confirming the increased potency of pralatrexate 
compared to MTX in antifolate-sensitive myeloma cell 
lines.
We investigated the mechanisms of apoptosis by 
examining the activation of pro-apoptotic proteins in 
pralatrexate treated myeloma cell lines. After 48 hours 
of pralatrexate exposure, the sensitive cell lines MM.1s, 
ARH-77 and PCNY-1B exhibited a concentration 
dependent cleavage of caspase 3 and caspase 9, key 
components of the cell-intrinsic apoptosis pathway, 
compared to untreated negative controls (Figure 2C, 
Supplementary Figure 2C). Exposure to 2 nM, 10 nM or 
100 nM of pralatrexate did not induce any cleavage in the 
resistant cell lines RPMI and U266. In addition, treatment 
with pralatrexate caused a decrease in the anti-apoptotic 
long form of Mcl-1 protein in sensitive cell lines. The Mcl-
1 protein, a Bcl-2 family member, has been demonstrated 
to be particularly important for the survival of myeloma 
cells [36, 37]. In the presence of increased pralatrexate 
concentrations, the expression of the 40 kDa isoform of 
Mcl-1 decreased in MM.1s, PCNY-1B and ARH-77 cells 
(Figure 2C). While the responses were concentration 
dependent, the range of Mcl-1 reduction spanned from 
total elimination (MM.1s) to moderately lower levels as 
seen for PCNY-1B. Incubation with pralatrexate did not 
alter the relative quantity of Mcl-1 in RPMI and U266 
cell lines, which is consistent across the cytotoxicity and 
apoptosis data. The addition of the pan-caspase inhibitor 
QVD (QVD-OPh: quinolyl-valyl-O-methylaspartyl-[-2, 
6-difluorophenoxy]-methyl ketone) diminished the level 
of apoptosis induced by PDX in the sensitive cell line 
MM.1s (Figure 2D), producing no effect on apoptosis in 
the non-responsive, resistant cell line U266.
Pralatrexate treatment blocks S-phase cell cycle 
progression in sensitive myeloma cell lines
As shown in Figure 3A, MM.1s cells treated with 
MTX or PDX exhibited a distinct pattern of cell cycle 
events compared to untreated cells as early as 12 hours 
after exposure to the drug. Pralatrexate or MTX treated 
MM.1s cells accumulated in early G1/S phase transition, 
as demonstrated through 7-AAD and Bromodeoxyuridine 
(BrdU) co-staining (Figure 3A). Drug-treated MM.1s 
cells were able to initiate DNA synthesis, visualized as 
an increase in incorporation of pulsed BrdU (S-phase). 
However, the cells were unable to progress through 
S-phase, as visualized as by an increase in BrdU+ diploid 
(2n) cells. This effect was time and concentration dependent 
(Figure 3B). The cell cycle analysis of resistant U266 cells 
was unaltered following treatment with PDX or MTX (1, 
3, 10 nM – data not shown). Interestingly, a similar effect 
was reported by Ramirez et al. who demonstrate resistance 
of U266 cells to the multi-targeted antifolated pemetrexed 
[38]. Across all sensitive cell lines, pralatrexate induced 
cell cycle arrest in a concentration dependent manner. 
These findings confirm the cell viability and apoptosis 
data above, demonstrating that the patterns of sensitivity 
and resistance remain intact across the assays, and that 
pralatrexate is superior to MTX in all assays.
The microenvironment does not alter patterns of 
sensitivity or resistance
Under normal host conditions, the bone marrow 
microenvironment contributes to the maintenance and 
progression of multiple myeloma tumor cells through 
cellular interactions as well as secretion of soluble factors. 
These stromal mediated mechanisms have been shown to 
impart drug-resistance to select chemotherapeutic agents 
[39, 40].
We examined the effects of IL-6 exposure, a 
principle cytokine important for myeloma cell proliferation 
and survival, on tumor cells treated with MTX and PDX. 
Co-incubation of the drug sensitive cell lines MM.1s and 
KMS-11 with IL-6 (5 ng/mL) and PDX did not cause a 
significant shift in the concentration dependent response, 
and did not change the IC
50
 value compared to cultures in 
the absence of cytokine (Figure 4A). Similarly, incubation 
with IL-6 did not sensitize the drug resistant cell line U266 
to PDX (Figure 4A). IL-6 did invoke an on target response 
in each of the cell lines as demonstrated by the induction of 
STAT3 phosphorylation at Tyr705 in MM.1s, KMS-11 and 
U266 cells exposed to IL-6 (Figure 4B). It should be noted 
that while each myeloma cell line exhibited distinctly 
different basal levels of STAT3 activation [41, 42]; this did 
not correlate with sensitivity to PDX nor MTX.
As myeloma is highly dependent on cell - cell 
interactions and paracrine signaling provided by the bone 
marrow microenvironment, co-culture experiments were 
performed to determine the import of these variables on 
drug sensitivity. Co-culture with the transformed HS-5 
BMSC line is thought to recapitulate aspects of the 
microenvironment influence and may mediate contact-
mediated drug resistance in some settings. PDX-sensitive 
(MM.1s) and resistant (U266) myeloma cell line were 
plated onto a layer of HS-5 cells and co-cultured for up 
to 48 hours in the presence of increasing doses of PDX. 
Those myeloma cell lines plated without stroma served as 
a control. Myeloma cells were selected by staining for the 
expression of the lymphocytic surface markers, including 
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Figure 2: Antifolates induce apoptosis in a dose-dependent manner in sensitive HMCLs. (A) Sensitive HMCLs - MM.1s 
(open square), KMS-11 (open diamond), PCNY-1B (open circle) and resistant HMCLs – U266 (filled square), CAG (filled triangle), ARP-
1 (filled inverted triangle) were incubated with increasing concentrations of either MTX or PDX for 48 hrs. Apoptosis was determined by 
flow cytometry using a fluorochrome-conjugated-AnnexinV marker. Untreated cells (untr) served as a negative control and bortezomib 
(10–50 nM) treated cells (not shown) served as a positive control for apoptotic cell death. (B) Sensitive HMCLs, MM.1s (white) and KMS-
11 (light gray), exhibit more apoptosis than resistant HMCLs, ARP-1 (dark gray) and U266 (black), after 48 hrs of exposure to 10 nM 
PDX. The statistical analysis uses data from three separate experiments. Paired student t-test generated p values: *p < 0.02, **p < 0.005, *** 
p < 0.001. (C) Western blot analysis depicting relative protein levels of full length and cleaved caspase 9, caspase 3, full length Mcl-1, and 
β-actin. HMCLs (U266, RPMI 8226, ARH-77, PCNY-1B, and MM.1s) were treated with 2, 10 or 100 nM PDX for 48 hrs. Artifact observed 
in U266 10 nM PDX treated Actin sample. When the X-ray film is pulled out it can cause scratches to appear on the film, causing such 
artifacts. (D) MM.1s (left panels) and U266 (right) were incubated with increasing amounts of PDX (0.5 nM – 100 nM) in the presence 
(black bars) or absence (white) of 100 μM of pancaspase inhibitor Q-VD-OPh (QVD). Data were collected at 24hrs (top panels) and 48hrs 
(bottom) of incubation. U = vehicle control cells, B = bortezomib treated cells (10 nM).
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CD38 (MM.1s) and CD138 (U266). Tumor cell viability 
was determined by the identification of the double positive 
CD138+/annexinV+ or CD38+/annexinV+ populations 
from the myeloma cell marker total subset (Figure 4D). 
The kinetics and concentration response to PDX were 
consistent with all the previous assays, confirming that 
these conditions did not change the patterns of sensitivity 
or resistance among the cell lines, nor did it affect the 
differential potency of the two drugs. These data suggest 
the protective effects of IL-6 and the bone marrow 
microenvironment seen with some agents does not alter 
patterns of PDX sensitivity.
Sensitivity to pralatrexate correlates with RFC 
expression
To identify discrete biomarkers of sensitivity 
and resistance to pralatrexate, we surveyed a panel of 
pharmacologic determinants established as possibly 
contributing to the phenotype. A subset of PDX-sensitive 
(MM.1s, KMS-11) and resistant (U266, CAG) myeloma 
cells were treated with increasing concentrations of PDX 
and expression of DHFR protein were quantitated by 
western blot over a 48-hour period (Figure 5A, 5B). Basal 
levels of DHFR protein in each cell line were low, and in 
Figure 3: Antifolates cause cell-cycle disruption in MM.1s myeloma tumor cells. MM.1s cells were incubated with either PDX 
(1 nM, 3 nM, 10 nM) or MTX (10 nM, 30 nM 100 nM) for 24 hrs. Time points were taken at 6, 12 and 24 hrs. Thirty minutes prior to 
isolation at each time point MM.1s cells were pulsed with Bromodeoxyuridine (BrdU). (A) A flow cytometry dot plot array shows 7AAD/
αBrdU co-stained MM.1s cells at 6 hrs, 12 hrs, and 24 hrs at single dose - PDX (3 nM) and MTX (30 nM). The gates define cells in the 
three stages of the cell cycle: G1, S-phase (S), and G2/mitosis (G2). (B) A graphical representation of the entire experimental data set. Drug 
concentrations listed on the x-axis are in nM.
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Figure 4: HMCLs retain sensitivity to PDX in the presence of microenvironment prosurvival factors. (A) A subset of 
HMCLs were cultured in the presence of IL-6 (5 ng/ml) for 24 hrs prior to incubation with increasing concentrations of PDX (0.3 nM–100 
nM). Cell viability was assayed after 48 hrs of PDX exposure. The curves are normalized to untreated cells (100%) and bortezomib (10–50 
nM) treated cells (0%). Data represent the mean ± SD of at least three experiments. (B) KMS-11, MM.1s and U266 cells were cultured 
for 24 hrs with or without IL-6 (5 ng/ml) and whole cells lysates were analyzed by western blot for phospho-STAT3 Tyr705 (pSTAT3), total 
STAT3 (STAT3). β-actin served as a loading control. (C) MM.1s and U266 cells were incubated on a monolayer of HS-5 bone marrow 
stroma-derived cells (BMSC) and incubated with increasing concentrations of PDX (MM.1s: 1 nM, 2 nM, 100 nM; U266: 2 nM, 10 nM, 
100 nM). Dual color flow cytometry plots depicting apoptotic (annexin V+) MM.1s (CD38+) cells at 24 hrs and 48 hrs. (D) The full data set 
of the apoptotic HMCL population depicting MM.1s cells (AnnexinV+ CD38+) alone (white), U266 cells (AnnexinV+ CD138+) alone (gray) 
and HS-5: HMCL co-culture respectively (black). Untr = untreated vehicle control cells.
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some cases even undetectable, in comparison to the drug 
treated samples. This may reflect a generally lower rate 
of proliferation compared to other lymphoproliferative 
malignancies. As observed in Figure 5A, the concentration 
dependent stabilization of DHFR protein was found in 
both sensitive and resistant cell lines, increases in DHFR 
protein levels in response to drug were substantially higher 
in the PDX resistant cell lines (U266, CAG) compared 
to PDX-sensitive lines (MM.1s, KMS-11). This fits with 
the established features of MTX resistance, wherein 
amplification of DHFR, for example, strongly correlates 
with MTX resistance.
To explore the significance of other pharmacologic 
and genetic determinants of resistance, we quantitated 
the expression levels of gene transcripts associated with 
antifolate sensitivity. The relative mRNA expression 
levels of four folate pathway genes (RFC, GGH, FPGS 
and DHFR) were examined in eight myeloma cell lines, 
including four resistant lines (ARP-1, CAG, RPMI 
8228, U266) and four sensitive lines (ARH-77, KMS-
11, MM.1s, PCNY-1B). While expression of each gene 
differed between the different cell lines (Supplementary 
Figure 3A), when the lines were grouped based on their 
pattern of sensitivity to PDX-sensitivity, a trend emerged 
(Figure 6A). As shown in Figure 6B, pralatrexate-resistant 
cell lines consistently expressed substantially lower levels 
of RFC mRNA compared to sensitive cell lines, a finding 
that was highly statistically significant (p < 0.0001). These 
data suggest RFC expression in myeloma tumor cells is 
the key biomarker of sensitivity to pralatrexate.
Efforts to corroborate the levels of RFC at the level 
of the protein were complicated by the fact that there are 
no reliable antibodies against RFC. Hence, we utilized a 
functional assay to quantitate radiolabeled MTX influx, 
as reported by Zhao et al. with an intent to correlate the 
rates of internalization with the pattern of pralatrexate 
and MTX sensitivity and RFC mRNA expression 
[43]. Cell lines were incubated with non-saturating 
extracellular concentrations of methotrexate spiked with 
[3H] MTX over one hour to measure the uptake of drug 
as a function of time. The transport was performed at pH 
7.4 to minimize the contribution of endogenous proton-
coupled folate transporter (PCFT) on MTX uptake [44, 
45]. The equilibrium is achieved relatively quickly as 
demonstrated by the flattening of the slope of intracellular 
MTX influx over time (Figure 6C). Drug sensitive MM.1s 
and KMS-11 cells exhibited significant internalization 
of MTX as determined by intracellular concentrations of 
MTX. Conversely, the drug resistant U266 cells, which 
expressed relatively low RFC mRNA, demonstrated a 
limited capacity to internalize MTX. The differential in 
MTX intracellular concentration between the sensitive 
cells and U266 was highly statistically significant (Figure 
6C, 6D; MM.1s v. U266 – p = 0.0297; KMS-11 vs U266 
– p = 0.0078). Individual statistical analyses for each time 
point within the linear range demonstrated that the influx 
rate of MTX in pralatrexate-resistant and sensitive cell 
lines differed substantially (Supplementary Figure 3B, 
3C). As expected, the drug resistant cell lines (U266, CAG 
and RPMI) exhibited lower intracellular concentrations 
of MTX compared to the sensitive cell lines (KMS-11, 
MM.1s and PCNY-1B; Figure 6C). Importantly, the results 
at the extremes of the data range demonstrate a direct 
correlation between increased RFC function and increased 
sensitivity to PDX in myeloma tumor cells.
DISCUSSION
While multiple myeloma is not thought of as 
a disease sensitive to antifolates, it is clear there are 
Figure 5: Antifolate-resistance in HMCLs correlates to the magnitude of DHFR protein upregulation in response to 
PDX. (A) PDX-sensitive cells MM.1s, KMS-11 and PDX-resistant cells U266, CAG were incubated with increasing concentrations of 
PDX (1, 2, 10, 100 nM) for 24 and 48 hrs. Whole cell lysates were run on a SDS-PAGE gel and protein expression analyzed by western 
blot. (B) The semi-quantitative densitometry data for the relative expression levels of DHFR (ratio of DHFR band intensity/beta-actin band 
intensity) for 48 hr samples in panel A. U = untreated cells, * denotes a non-specific band at 25 kDa in the KMS-11 & ARH-77 cell lines, 
proper band is below (arrow).
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a number of determinants that might influence the 
conclusion. First, methotrexate has been consistently 
shown to be inferior to pralatrexate, by at least a log-
fold across all the biochemical and physiological assays 
studied to date. Hence, it is possible this class of drugs 
is ‘overlooked’ based upon suboptimal experiences with 
earlier analogs. Second, it is clear that at least RFC, and 
likely other pharmacologic determinant like DHFR and 
FPGS, can influence disease sensitivity to the class. It 
is likely that identifying a multiple myeloma ‘sensitive’ 
population based on RFC expression would enrich for 
patients likely to respond.
Figure 6: RFC expression and function correlate with PDX-sensitivity in HMCLs. (A) Relative mRNA expression of folate 
pathway genes in PDX-senstive (white) and PDX-resistant (black) HMCLs. The gene transcripts analyzed by RT-qPCR analysis were 
RFC, FPGS, GGH and DHFR. Eight cell lines made up the panel of HMCLs, four resistant: CAG, U266, ARP-1, RPMI 8226 and four 
sensitive: PCNY-1B, ARH-77, KMS-11 and MM.1s. Messenger RNA levels from each respective gene transcript were normalized to beta-
actin and cyclophilin B. The data represent a minimum of three individual experiments. The box whisker plot demarcations: mean (line), 
box (25th-75th percentile), whiskers (minimium and maximium). The two-tailed p values were obtained through an unpaired Student t-test. 
(B) Correlation between RFC mRNA expression levels in 8 HMCL lines (open symbols = PDX-sensitive, filled symbols = PDX-resistant) 
and their respective IC
50
 values for PDX. The p value is one-tailed, r value = Pearson correlation coefficient. (C) The net uptake kinetics 
of MTX in a panel of resistant (black, solid line) and sensitive (open, dashed line) HMCLs. Cells were exposed to 1 μM MTX spiked with 
[3H-MTX] and samples were taken at 1, 2, 3, 5, 15, 30 and 60 min after the initial exposure. The main chart displays linear data obtained 
from 0-5 mins; the inset shows all data points 0–60 mins. Data are from a single experiment, which is representative of repeat studies. (D) 
Data compiled from a set of experiments comparing intracellular MTX level differences at 3 minutes after 3H-MTX incubation in KMS-11, 
MM.1s and U266 cells. The p-value was calculated by multiple t-test analysis and significance determined using the Holm-Sidak method 
(alpha = 5.0%) *p < 0.05, **p < 0.005.
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These data have consistently demonstrated that 
across all assays, there is a clear dichotomy among the 
myeloma cells studied: they are either highly sensitive to 
MTX and pralatrexate, or they are highly resistant to these 
agents. The classification of these two types of cells was 
corroborated across a variety of assays ranging from Cell 
Titer Glo to Annexin V and caspase 3 and 9 cleavage, to the 
cell cycle analysis. No cell line was found to be resistant 
in one assay and sensitive in another. There was a clear 
separation between the two phenotypes of myeloma cells.
Multiple myeloma is highly dependent on 
cytokine signaling pathways, be it IL-6, other paracrine 
pathways, or direct cell: cell mediated contact with the 
stromal microenvironment. It has been well established 
in a variety of myeloma models that all of these factors 
can contribute to drug resistance, and identifying drugs 
that maintain their activity irrespective of these stromal 
factors is an important goal in myeloma research. It has 
been demonstrated that the stromal environment plays an 
important role in cellular resistance to drugs including 
dexamethasone and doxorubicin. These factors did not 
have any impact on pralatrexate or methotrexate sensitivity 
in our analysis. Importantly, these data suggest that the 
potent cytotoxicity of pralatrexate is mediated independent 
of IL-6. Interestingly, IL-6 induced pSTAT3 expression, 
which has also been correlated with anti-apoptotic, pro-
proliferation signaling pathways [46–48].
Differential expression of RFC appears to be 
a critical pharmacologic determinant in pralatrexate 
sensitivity in MM, which is notable since the drug was 
optimized for affinity to this transporter. Consistent with 
all the assay data, sensitive lines successfully internalized 
higher quantities of anti-folate (MTX), while resistant cell 
lines were found to have significantly lower intracellular 
concentrations of MTX. These internalization experiments 
correlated with the sensitivity pattern, RFC mRNA data 
and all the cytotoxicity data. Ideally, it would be valuable 
to know if RFC expression itself is prognostic, and 
whether a rapid assay could be developed to identify MM 
patient tumor cells as high versus low RFC expressers 
in a clinical setting. Gene expression profiling of tumor 
cells from patients may provide a means to study this 
hypothesis in a prospective manner.
In conclusion, we demonstrate that pralatrexate has 
promising pre-clinical activity in a subset of MM cell lines. 
Baseline RFC mRNA expression and induced expression 
of DHFR after exposure are functional pharmacologic 
biomarkers in this setting. Clinically, these data create a 
clinical trial scenario where pralatrexate could be studied 
in an all-commerce phase 2 study, with analysis of 
patient derived tissue for RFC and other pharmacologic 
determinants. This study could then be followed by a study 
where the biomarker of interest, in this case RFC, is used to 
screen patients for eligibility. This approach could allow for 
the identification of a novel drug in the disease, and establish 
a means to treat only those patients likely to benefit.
MATERIALS AND METHODS
Cell lines
The human myeloma cell lines used in these studies 
included U266, RPMI-8226 (obtained from American 
Tissue Culture Collection - ATCC), MM.1s, ARP-1, ARH-
77, CAG, SK-MM2, KMS-11 (provided by S. Chen-
Kiang, Weill Cornell Medical College, New York, NY) and 
PCNY-1B (provided by HJ Cho, Icahn School of Medicine 
at Mt. Sinai). All myeloma cell lines, save PCNY-1B, were 
cultured in RPMI-1640 (Life Technologies) supplemented 
with 10% fetal bovine serum (FBS; Sigma-Aldrich), and 
20 µg/ml Gentamycin (Life Technologies). PCNY-1B 
was cultured in X-Vivo 15 (Lonza Walkersville, Inc.), 
supplemented with 10% pooled human serum (Omega 
Scientific, Inc.). The human bone-marrow stromal cell 
line HS-5 (provided by S. Chen-Kiang) was cultured in 
DMEM (ATCC) supplemented with 10% FBS and 20µg/
ml Gentamycin. All cell cultures were maintained at 37° C 
with 5% CO2 in 95% relative humidity.
Drugs and reagents
Pralatrexate was purchased from Selleckchem. All 
other drugs and chemical entities were purchased from 
Sigma Aldrich. Antibodies for Western blotting were 
obtained as follows: beta-actin (abcam ACTN05), caspase 
3 (Santa Cruz #7272); (Cell Signaling #9662), caspase 9 
(Signaling #9502), DHFR (Sigma WH0001714M1), Mcl-1 
(Signaling #4572), Stat3 (Signaling #9132), Phospho-Stat3 
(Signaling #9145), PARP (BD Biosciences #556362).
Cell viability assay
Cell viability was measured using a luciferase-
coupled ATP quantitation assay (CellTiter-Glo, Promega). 
Cells were plated at a concentration of 1.5 × 105 cells/ml 
at a final volume of 200 µl per well in a 96-well plate. The 
assay plates were incubated for 24, 48 or 72 h at 37° C 
in the presence or absence of drug. In order to determine 
the impact of caspase cleavage on apoptosis cells were 
incubated with 50 mM pan caspase inhibitor, QVD-OPH 
(catalogue number OPH109, MP Biochemicals, Aurora, 
OH). At the appropriate time points, cells were harvested 
and transferred to opaque, white 96-well plates at which 
time the CellTiter-Glo reagent was added at a volumetric 
ratio of 1:1. The intensity of luminescence in the plates 
was measured using a SynergyH1 plate reader (BioTek).
Apoptosis assay
Apoptotic cells were determined by Annexin-V+ 
using a staining method described previously [49]. 
Cells were resuspended in a small volume (100 µL) 
of 1× binding buffer (BD Bioscience), and incubated 
with Annexin V-FITC (BD Biosciences) and 5 µL of 
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7-Aminoactinomycin D (7-AAD; BD Biosciences) at 
room temperature, in the dark for 20 minutes. Untreated 
cells stained with Annexin V only or 7-AAD only served 
as single color controls. Cells were then fixed in 100µL 
of 4% paraformaldehyde (Sigma- Aldrich), collected by 
flow cytometry on a FACSCalibur (BD Bioscience) using 
CellQuest and analyzed by Flowjo.
Western blot analysis
Protein lysates were prepared by freeze-thawing 
cells in lysis buffer (350 mmol/L NaCl, 20 mmol/L HEPES 
(pH 7.9), 0.2% NP-40, 1 mmol/L MgCl2, 1 mmol/L 
DTT, 20% glycerol, 2 mmol/L sodium orthovanadate, 
10 mmol/L b-glycerol phosphate, and protease inhibitor 
(Calbiochem). Protein concentration was determined 
using the Bradford assay (Bio-Rad) according to the 
manufacturer’s instructions. Lysates (10 μg) was run on 
an SDS-PAGE gel and transferred to a polyvinylidene 
difluoride membrane (Millipore). Blocking and antibody 
dilutions were made in 5% nonfat dry milk (NFDM) in 
TBS-T [10 mmol/L Tris base, 150 mmol/L NaCl, 0.01% 
(v/ v) Tween 20; Sigma-Aldrich) or 5% bovine serum 
albumin (BSA). Blots were visualized with Supersignal 
West Femto Substrate (Thermo Scientific). Densitometry 
analysis was performed on ImageJ (NIH. Bethesda, MD) 
per the manufacturer’s recommendations using beta-actin 
as a reference control.
Cell-cycle BrdU assay
The flow cytometry-based cell cycle progression 
assay was carried out as described by the manufacturer 
of BD BrdU FITC Assay (BD Biosciences). MM.1s cells 
(2.0 × 105 cells/mL) were incubated with drug or vehicle 
for specified durations. One hour prior to collection 
of each time point the cells were incubated with BrdU 
(10 μM). After incubation the cells were washed (1× 
PBS), fixed, permeabilized and stained as described 
by the manufacturer. The DNA was co-stained with 
7-AAD and the cells were visualized on a FACSCalibur 
cytometer.
RNA isolation
Cell pellets were solubilized in 1 ml TRI reagent 
(MRC, Cincinnati, OH) and then sonicated for 10s 
on ice with a Sonic Dismembrator (Model 100 Fisher 
Scientific, Weltham MA). Each sample was mixed with 
100 μl bromochlorophenol (MRC) and incubated at room 
temperature for 10 min, centrifuged at 14,000 × g, 4° C for 
10 min. The aqueous phase was collected, and RNA was 
precipitated by adding 500μl isopropanol (Sigma-Aldrich, 
St. Louis, MO) and incubated at room temperature for 
10 min, followed by centrifugation at 13,000 × g, 4° C for 
15 min. The RNA pellet was washed with 75% ethanol 
(Sigma-Aldrich) and centrifuged again as in the previous 
step. The RNA pellet was air-dried and then re-suspended 
in 50–100 μl nuclease-free water and incubated at 
70° C for 5 min. The concentration was determined 
by measuring the optical density of diluted samples at 
260 nm in a Beckman Coulter DU530 spectrophotometer 
(Beckman Coulter Inc., Fullerton, CA).
Gene expression analysis
Quantitative real-time RT-PCR (qRT-PCR) was 
carried out as previously described [50]. Taqman primer 
sets (Applied Biosciences) for the genes of interest 
in these experiments included the following: β-actin 
(Hs00181698_m1), cyclophilin B (Hx00168719_m1), 
SLC19a1 (Hs00953344_m1), FPGS (Hs00191956_m1), 
GGH (Hs00914163_m1) and DHFR (Hs00758822_s1). 
Relative expression was calculated against the geometric 
mean of the reference primers (β-actin and cyclophilin B) 
by the following formula: relative expression = 2-[ΔCt 
(sample) - ΔCt (reference)], where ΔCt = Ct (test) – Ct 
(baseline control).
Radiolabeled MTX membrane flux assay
Cells were pelleted and washed twice in HBS 
buffer (20 mM HEPES, 140 mM NaCl, 5 mM KCl, 
2 mM MgCl2, and 5 mM dextrose; adjusted with 1 N 
NaOH to achieve a pH of 7.4). Cells were resuspended in 
HBS buffer at the final density of 10–15 × 10e6 cells/ml, 
transferred in stirrer-glass tubes and incubated in a 37° C 
water bath for 20 min. Then, MTX spiked with [3H] MTX 
was added to a final concentration of 1 μM and uptake was 
performed at a pH 7.4. Aliquots from the cell suspension 
were collected over time and the reaction was stopped by 
injection of 10 volumes of ice-cold HBS buffer. The cells 
were washed and digested with 500 ml 0.2 N NaOH at 
65° C for 45 min. Lysates were assessed for tritium on 
a liquid scintillation β-counter and protein concentration 
was determined by BCA assay (Thermo Fisher Scientific, 
Waltham, MA). Intracellular MTX was expressed as 
picomoles per milligram of protein.
Statistical analyses
GraphPad Prism 5.0/6.0 was used to tabulate, chart 
and calculate all data and statistics. Unless noted all p 
values are obtained by implementing a paired Student’s 
t-test, all values yielding a p < 0.05 are considered 
significant values. Unless otherwise noted: *p < 0.05, **p 
< 0.01, ***p < 0.001.
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